BTF3P15

Across TCGA pan-cancer cohorts, BTF3P15 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated BTF3P15 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher BTF3P15 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTF3P15 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

STAD, LIHC, and UCS are the cancer types where BTF3P15 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.453	0.735	.001	54	view →
LIHC	OS	Tertile	All	0.195	0.777	.005	54	view →
UCS	OS	Tertile	III,IV	0.102	0.591	<.001	36	view →
SKCM	OS	Tertile	II,III,IV	0.318	0.742	.011	27	view →
THYM	DFS	Tertile	III,IV	0.205	0.774	.007	27	view →
GBM	OS	Tertile	All	0.217	0.427	.036	18	view →
TGCT	DFS	Tertile	All	0.090	0.807	<.001	18	view →
CESC	OS	Tertile	All	0.724	0.874	.027	18	view →
LUAD	DFS	Tertile	IV	1.000	0.285	.042	12	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

BTF3P15–STAD (DFS)

Open the STAD breakdown →